Trial Profile
Non-Interventional Study on the Tolerability and Efficacy of IVIG
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Graft-versus-host disease; Immunodeficiency disorders
- Focus Adverse reactions
- Acronyms GammaTrack
- Sponsors Octapharma
- 22 Sep 2020 Status changed from recruiting to completed.
- 20 Jun 2018 Planned number of patients changed from 1000 to 500.
- 20 Jun 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.